Zesheng An
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 06, 2024
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.
Journal: Frontiers in immunology
Published: May 18, 2023
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.
Journal: medRxiv : the preprint server for health sciences
Published: March 30, 2023
A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 21, 2022
Understanding Suboptimal Response to Immune Checkpoint Inhibitors.
Journal: Advanced biology
Published: December 14, 2021
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Journal: Cancer immunology research
Published: July 07, 2021
FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Journal: Current pharmaceutical biotechnology
Published: March 01, 2021
RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.
RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.
Journal: Urologic oncology
Published: August 30, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026